Ken Fisher Fisher Asset Management
Ken Fisher is the founder and executive chairman of Fisher Investments, a global money management firm overseeing billions of dollars in assets. He gained early recognition for pioneering the use of the price-to-sales ratio in stock analysis and wrote the long-running “Portfolio Strategy” column in Forbes. Over the years, Fisher has authored numerous books on investing and wealth management, many of which have become bestsellers.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$1.88B |
| 2 |
Pfizer
PFE
|
+$1.41B |
| 3 |
iShares 7-10 Year Treasury Bond ETF
IEF
|
+$1.17B |
| 4 |
Cisco
CSCO
|
+$1.1B |
| 5 |
Novartis
NVS
|
+$984M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$1.21B |
| 2 |
Adobe
ADBE
|
+$1.06B |
| 3 |
Stryker
SYK
|
+$955M |
| 4 |
Boston Scientific
BSX
|
+$695M |
| 5 |
Banco Santander
SAN
|
+$684M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.16% |
| 2 | Financials | 17.3% |
| 3 | Industrials | 10.45% |
| 4 | Healthcare | 9.91% |
| 5 | Energy | 8.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
351
Trustmark
TRMK
$2.76B
| $15.6M | 0.01% |
370,509
-754
| -0.2% | -$31.8K |
|
352
Pinnacle Financial Partners Inc
PNFP
$15.9B
| $14.9M | 0.01% |
+173,476
| New | +$16.1M |
|
353
WSFS Financial
WSFS
$4.12B
| $14.9M | 0.01% |
227,911
-35
| -0% | -$2.21K |
|
354
Prestige Consumer Healthcare
PBH
$2.38B
| $14.9M | 0.01% |
251,165
-22,720
| -8% | -$1.47M |
|
355
Avient
AVNT
$3.33B
| $14.9M | 0.01% |
409,583
-3,066
| -0.7% | -$114K |
|
356
Tanger
SKT
$4.67B
| $14.3M | ﹤0.01% |
421,486
-38,456
| -8% | -$1.32M |
|
357
LXP Industrial Trust
LXP
$3.57B
| $14.3M | ﹤0.01% |
308,397
-490
| -0.2% | -$24K |
|
358
Zscaler
ZS
$24.5B
| $14.3M | ﹤0.01% |
101,657
-1,311
| -1% | -$233K |
|
359
Box
BOX
$4.37B
| $14M | ﹤0.01% |
593,865
-13,273
| -2% | -$334K |
|
360
Vertex Pharmaceuticals
VRTX
$121B
| $13.9M | ﹤0.01% |
31,158
+5,940
| +24% | +$2.77M |
|
361
Chord Energy
CHRD
$7.9B
| $13.9M | ﹤0.01% |
97,775
+14,493
| +17% | +$1.58M |
|
362
Alkermes
ALKS
$8.22B
| $13.8M | ﹤0.01% |
390,479
-14
| -0% | -$434 |
|
363
First Merchants
FRME
$2.68B
| $13.5M | ﹤0.01% |
348,861
-26,415
| -7% | -$1.03M |
|
364
Ameris Bancorp
ABCB
$5.85B
| $13.4M | ﹤0.01% |
172,000
-19,110
| -10% | -$1.52M |
|
365
Constellium
CSTM
$3.76B
| $13.3M | ﹤0.01% |
539,451
+529,278
| +5,203% | +$12.6M |
|
366
Tesla
TSLA
$1.23T
| $12.9M | ﹤0.01% |
34,755
-441
| -1% | -$182K |
|
367
Atlantic Union Bankshares
AUB
$6.02B
| $12.9M | ﹤0.01% |
360,253
-38
| -0% | -$1.43K |
|
368
Warner Bros
WBD
$65.9B
| $12.9M | ﹤0.01% |
468,145
-44,083
| -9% | -$1.23M |
|
369
Credicorp
BAP
$31.8B
| $12.7M | ﹤0.01% |
37,378
-13,738
| -27% | -$4.61M |
|
370
Urban Edge Properties
UE
$2.86B
| $12.7M | ﹤0.01% |
633,243
-23,251
| -4% | -$467K |
|
371
Commault Systems
CVLT
$4.88B
| $12.6M | ﹤0.01% |
162,348
-16
| -0% | -$1.52K |
|
372
Viavi Solutions
VIAV
$9.12B
| $12.6M | ﹤0.01% |
379,600
-63,696
| -14% | -$1.68M |
|
373
Domino's
DPZ
$11.5B
| $12.4M | ﹤0.01% |
34,481
-151
| -0.4% | -$59.6K |
|
374
Core Laboratories
CLB
$488M
| $12.4M | ﹤0.01% |
736,747
-38,232
| -5% | -$684K |
|
375
Bristol-Myers Squibb
BMY
$133B
| $12.4M | ﹤0.01% |
203,654
-1,074
| -0.5% | -$62.6K |
|
Similar funds
Ken Fisher's Q1 2026 Portfolio in Review
As of Q1 2026, Ken Fisher held 1,133 positions worth $295B, up 0.65% from $293B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Ken Fisher's Q1 2026 filing shows 116 new, 416 increased, 461 reduced and 117 closed positions. Its largest new stake was Portfolio Building Block World Pharma and Biotech Index ETF: 28,040,859 shares worth $717M. The largest sale was Abbott, an estimated $1.21B.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 25% a quarter earlier, followed by Financials and Industrials.
- Ken Fisher's largest Q1 2026 buy was Portfolio Building Block World Pharma and Biotech Index ETF: 28,040,859 shares worth $717M.
- Ken Fisher added most to AbbVie in Q1 2026, an estimated $1.88B increase.
- Ken Fisher's biggest Q1 2026 reduction was Abbott, cutting an estimated $1.21B.
- Ken Fisher fully exited Trip.com Group in Q1 2026, selling an estimated $175M.
- Ken Fisher's ten largest holdings make up 33% of its $295B portfolio in Q1 2026.
- Ken Fisher opened 116 new positions and closed 117 in Q1 2026.
- Ken Fisher's portfolio value rose 0.65% quarter-over-quarter to $295B.
Based on Fisher Asset Management's 13F filing for Q1 2026, filed 5 May 2026.